Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Service d'aide à la décision clinique
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    9 2 0 0


La Presse Médicale
Volume 38, n° 5
pages 799-807 (mai 2009)
Doi : 10.1016/j.lpm.2009.01.012
Indications de l’anakinra
Indications of anakinra
 

Karine Chauffier, Jonathan London, Constance Beaudouin, Bruno Fautrel
Service de rhumatologie, GH Pitié-Salpêtrière, AP-HP, Université Paris 6 Pierre et Marie Curie, UFR de médecine, Site Pitié-Salpêtrière, F-75013 Paris, France 

Bruno Fautrel, Service de rhumatologie, GH Pitié Salpêtrière, 83 boulevard de l’Hôpital, F-75013 Paris, France.
Points essentiels

L’efficacité symptomatique et structurale de l’anakinra dans la polyarthrite rhumatoïde a été démontrée dans plusieurs essais thérapeutiques. Cependant, sa place dans cette indication semble réduite par rapport aux autres biothérapies.

L’anakinra semble être un traitement prometteur dans la maladie de Still de l’adulte ou de l’enfant, après échec des corticoïdes et du méthotrexate.

L’anakinra est un traitement de choix pour certains syndromes auto-inflammatoires héréditaires, dans lesquels son efficacité est spectaculaire.

L’anakinra pourrait être intéressant au cours des dermatoses neutrophiliques et des polychondrites atrophiantes réfractaires aux thérapeutiques usuelles.

Les réactions au point d’injection et les infections sont les 2 principaux effets indésirables de l’anakinra.

The full text of this article is available in PDF format.
Key points

The efficacy of anakinra on both RA-related symptoms and structural damage has been demonstrated in several randomized controlled trials. However, its interest seems limited with regards to other biologic agents.

Anakinra seems promising in the treatment of childhood or adult onset Still disease, after the failure of both high dose steroids and methotrexate.

The efficacy of anakinra is dramatic in several hereditary auto-inflammatory syndromes.

Anakinra could be an interesting drug for the treatment of neutrophilic dermatosis or relapsing chondritis, refractory to conventional agents.

Injection site reactions and infections are the 2 main anakinra-related side effects.

The full text of this article is available in PDF format.


© 2009  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline